Results 81 to 90 of about 2,519 (184)

Ischemic stroke following reversal of dabigatran with idarucizumab in spontaneous subdural hematoma in cerebral venous thrombosis [PDF]

Spontaneous subdural hematomas (SDH) are an unusual but potentially devastating complication of oral anticoagulation. Emergency management of subdural hematomas following oral anticoagulant therapy consists of reversal of anticoagulation coupled with ...
Acharya, Ullas V., Santhosh, Thanisha, Krishnan, Pramod, Anusha, Donti R., Kalashetty, Mallikarjun   +4 more
core   +1 more source

Intracerebral Hemorrhage: Advances, Knowledge Gaps, and Future Directions

MedComm, Volume 6, Issue 11, November 2025.
This review provides a comprehensive synthesis of current research on the epidemiology, pathophysiological mechanisms, imaging characteristics, treatment delays, clinical management strategies, neural repair, and prognostic prediction of intracerebral hemorrhage (ICH).
Tao Liu, Weiwei Jiang, Minzhi Zhang, Shangzhi Xiong, Linan Chen, Xiaoying Chen, Rongcai Jiang   +6 more
wiley   +1 more source

Successful intravenous thrombolysis in acute ischemic stroke after reversal of dabigatran etexilate with idarucizumab at the end of therapeutic time window

Turkish Journal of Emergency Medicine, 2020
Dabigatran is a direct oral anticoagulant that is widely used for stroke prevention in patients with atrial fibrillation. We report a case of an 80-year-old stroke patient on dabigatran for permanent atrial fibrillation, who presented with an initial ...
Gorana Vukorepa, Sabina Deveđija*, Miljenko Crnjaković, Mirna Karakaš, Zeljka Cuk   +4 more
doaj   +1 more source

Stroke prevention in atrial fibrillation: A narrative review of current evidence and emerging strategies

European Journal of Clinical Investigation, Volume 55, Issue 9, September 2025.
Effective stroke prevention in AF requires a comprehensive holistic approach incorporating appropriate risk stratification, guideline‐adherent anticoagulation and management of underlying cardiovascular conditions and other comorbidities. The ABC pathway, supported by characterisation using the 4S‐AF framework, provides a structured approach to ...
Amir Askarinejad, Deirdre A. Lane, Parham Sadeghipour, Majid Haghjoo, Gregory Y. H. Lip   +4 more
wiley   +1 more source

Left atrial intramural hematoma following right atrial catheter ablation: A rare case involving coronary sinus injury

Journal of Arrhythmia, Volume 41, Issue 4, August 2025.
Left atrial intramural hematoma (LAIH) is an exceedingly rare complication that occurs following catheter ablation in the right atrium. The present case is the first to implicate coronary sinus catheter manipulation—rather than left atrial intervention—as a potential mechanism of LAIH.
Mina Hatsuno, Ken Kobayashi, Kenta Tsutsui, Yuji Watari, Ken Kozuma   +4 more
wiley   +1 more source

Successful thrombolysis with recombinant tissue plasminogen activator after antagonizing dabigatran by idarucizumab: a case report [PDF]

, 2016
Background Effective anticoagulation routinely precludes patients from receiving intravenous thrombolysis with recombinant tissue plasminogen activator to reverse severe symptoms of ischemic stroke.
Pawel Kermer, Gawehn, Annemarie, Kaste, Matthias, Kermer, Pawel, Heuschkel, Christian, Annemarie Gawehn, Ayari, Yassine, Yassine Ayari, Christian Heuschkel, Matthias Kaste   +9 more
core   +2 more sources

Data_Sheet_1_Dabigatran Reversal With Idarucizumab and In-Hospital Mortality in Intracranial Hemorrhage: A Systematic Review of Real-Life Data From Case Reports and Case Series.docx

, 2021
Background: Intracranial hemorrhage is a severe and possibly fatal consequence of anticoagulation therapy. Idarucizumab is used in dabigatran-treated patients suffering from intracranial hemorrhage (ICH) to reverse the anticoagulant effect of dabigatran.
George Ntaios (5196278), Dimitrios Sagris (5196272), Janja Pretnar Oblak (10915116), Mišo Šabovič (10915119), Senta Frol (10915113)   +4 more
core   +1 more source

2025 Guidelines for direct oral anticoagulants: a practical guidance on the prescription, laboratory testing, peri‐operative and bleeding management

Internal Medicine Journal, Volume 55, Issue 7, Page 1174-1183, July 2025.
Abstract Direct oral anticoagulants (DOACs) are widely prescribed to prevent and treat venous and arterial thromboembolism, supported by published evidence, and are preferred over warfarin in many guidelines. Although the risk of major bleeding, in particular intracranial haemorrhage (ICH), is decreased with DOACs, gastrointestinal bleeding is ...
Huyen A. Tran, Eileen Merriman, Ross Baker, Jennifer Curnow, Laura Young, Chee Wee Tan, Simon McRae, Sanjeev D. Chunilal   +7 more
wiley   +1 more source

Acute Stroke Despite Dabigatran Anticoagulation Treated with Idarucizumab and Intravenous Tissue Plasminogen Activator [PDF]

, 2017
Dabigatran is a direct thrombin inhibitor used to reduce the risk of stroke in patients with nonvalvular atrial fibrillation. For patients who present with an acute stroke despite dabigatran therapy, clinical data on the use of intravenous tissue ...
Brittany R. Traylor, David P. Richman, Kwan L. Ng, Manjunath, Rashmi, Richman, David P, Traylor, Brittany R, Ng, Kwan L, Bissig, David, David Bissig, Rashmi Manjunath   +9 more
core   +1 more source

Idarucizumab for dabigatran reversal

Thrombosis research, 2023
Background: Idarucizumab has been approved to reverse the anticoagulant effect of dabigatran. However, there is little knowledge of the effectiveness and safety of idarucizumab in daily practice. Aims: This systematic review and meta-analysis aims to evaluate the use, effectiveness and outcomes of idarucizumab.
van der Horst, S. F. B., Martens, E. S. L., den Exter, P. L., Bos, M. H. A., van Mens, T. E., Huisman, M. V., Klok, F. A.   +6 more
openaire   +1 more source